Free Trial

HUTCHMED (LON:HCM) Stock Crosses Below 200 Day Moving Average - Here's What Happened

HUTCHMED logo with Medical background

HUTCHMED (China) Limited (LON:HCM - Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 274.45 ($3.39) and traded as low as GBX 232.04 ($2.87). HUTCHMED shares last traded at GBX 234 ($2.89), with a volume of 35,188 shares changing hands.

HUTCHMED Trading Down 5.4 %

The company has a debt-to-equity ratio of 11.78, a current ratio of 2.81 and a quick ratio of 2.97. The company has a market cap of £1.88 billion, a P/E ratio of -5,500.00 and a beta of 0.76. The stock's 50-day moving average is GBX 253.54 and its two-hundred day moving average is GBX 274.22.

HUTCHMED Company Profile

(Get Free Report)

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S. We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange's AIM market (Nasdaq/AIM:HCM; HKEX:13).

Read More

Should You Invest $1,000 in HUTCHMED Right Now?

Before you consider HUTCHMED, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.

While HUTCHMED currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines